|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 2 | Expression of Transforming Growth Factor-β1 by Pancreatic Stellate Cells and Its Implications for Matrix Secretion and Turnover in Chronic Pancreatitis显示文摘 | Fanny Wai-Tsing Shek Robert Christopher Benyon Fiona Mairi Walker Peter Raymond McCrudden Sylvia Lin Foon Pender Elizabeth Jean Williams Penelope Ann Johnson Colin David Johnson Adrian Calvin Bateman David Roger Fine John Peter Iredale | 2002 | The American Journal of Pathology2002，，5： | 2 |
| 3 | Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis显示文摘AIM To confirm previous conclusions on Saccharomyces cerevisiae(S. cerevisiae) CNCM I-3856 for irritable bowel syndrome(IBS) management.METHODS An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal(GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve(AUC) and weekly means], responder status, and bowel movements(stool frequency and consistency). Statistical analyses were conducted in Intent to Treat(ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline('IBS-C ≥ 2 subpopulation').RESULTS S. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC(W5-W8)]with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group(P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group(P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit(a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder(reduction of 1 a.u. of abdominal pain/discomfort) compared with subjects in the Placebo group(P = 0.0240). At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as 'normal' compared to Placebo(respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003). Similar results were seen in the IBS-C ≥ 2 subpopulation(Active group: 3.14 ± 1.219 a.u. vs Placebo group: 2.59 ± 1.017 a.u., P = 0.0009).CONCLUSION This meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations. | Amélie Cayzeele-Decherf Fanny Pélerin Sébastien Leuillet Benoit Douillard Béatrice Housez Murielle Cazaubiel Gunnard K Jacobson Peter Jüsten Pierre Desreumaux | 2017 | World Journal of Gastroenterology2017，23，2： | 2 |
| 4 | Micro RNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis显示文摘 | Fanni Gelley Gergely Zadori Balazs Nemes Matteo Fassan Gabor Lendvai Eniko Sarvary Attila Doros Zsuzsanna Gerlei Peter Nagy Zsuzsa Schaff Andras Kiss | 2014 | J Gastroenterol Hepatol2014，，1： | 1 |
| 5 | Role of endogenous interleuldn-12 in immune response to staphylococcal enterotoxin B in mice 显示文摘 | FANNY N L SANDRINE F PETER S | 2001 | Infection and Immunity2001，69，9： | 1 |
| 6 | Collective contributions to career efficacy in adolescents: A cross-cultural study显示文摘 | Fanny M. Cheung Sarah L.Y. Wan Weiqiao Fan Frederick Leong Peter C.H. Mok | 2013 | Journal of Vocational Behavior2013，，3： | 1 |
| 7 | A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome显示文摘 | Guillaume Pineton de Chambrun Christel Neut Amélie Chau Murielle Cazaubiel Fanny Pelerin Peter Justen Pierre Desreumaux | 2014 | Digestive and Liver Disease2014，，： | 1 |
| 8 | Expression of Transforming Growth Factor-β1 by Pancreatic Stellate Cells and Its Implications for Matrix Secretion and Turnover in Chronic Pancreatitis显示文摘 | Fanny Wai-Tsing Shek Robert Christopher Benyon Fiona Mairi Walker Peter Raymond McCrudden Sylvia Lin Foon Pender Elizabeth Jean Williams Penelope Ann Johnson Colin David Johnson Adrian Calvin Bateman David Roger Fine John Peter Iredale | 2002 | The American Journal of Pathology2002，，5： | 1 |
| 9 | Access to biologicals in Crohn's disease in ten European countries显示文摘AIM To analyze access(availability, affordability and acceptability) to biologicals for Crohn's disease(CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development.METHODS A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals. An availability score was developed to evaluate the restrictiveness of eligibility and administrative criteria applied in the countries. Affordability was defined as the annual cost of treatment as a share of gross domestic product(GDP) per capita. Correlations with the uptake of biologicals, dimensions of access and GDP per capita were calculated.RESULTS At the time of the survey, infliximab and adalimumab were reimbursed in all ten countries, and vedolizumab was reimbursed in five countries(France, Germany, Latvia, Slovakia, Sweden). Reimbursement criteria were the least strict in Sweden and Germany, and the strictest in Hungary, Poland and Slovakia. Between countries, the annual cost of different biological treatments differed 1.6-3.3-fold. Treatments were the most affordable in Sweden(13%-37% of the GDP per capita) and the least affordable in the Central and Eastern European countries, especially in Hungary(87%-124%) and Romania(141%-277%). Biosimilars made treatments more affordable by driving down the annual costs. The number of patients with CD on biologicals per 100000 population was strongly correlated with GDP per capita(0.91), although substantial differences were found in the uptake among countries with similar economic development. Correlation between the number of patients with CD on biologicals per 100000 population and the availability and affordability was also strong(-0.75,-0.69 respectively). CONCLUSION Substantial inequalities in access to biologicals were largely associated with GDP. To explain differences in access among countries with similar development needs further research on acceptance. | Márta Péntek Peter L Lakatos Talitha Oorsprong László Gulácsi Milena Pavlova Wim Groot Fanni Rencz Valentin Brodszky Petra Baji Crohn’s Disease Research Group | 2017 | World Journal of Gastroenterology2017，23，34： | 0 |
| 10 | 通过核心蛋白簇分析鉴定导致甲硝唑耐药的幽门螺杆菌变异位点显示文摘背景:在根治幽门螺杆菌(Hp)的标准三联治疗中,甲硝唑是其中的一种一线药物。因此,甲硝唑耐药是一个重大健康问题。RdxA失活被认为是甲硝唑耐药的主要机制。然而,表达功能性RdxA蛋白的Hp菌珠更容易对甲硝唑耐药,提示还存在其他一些导致甲硝唑耐药的机制。方法:我们对121份Hp菌珠进行了全基因组测序,其中73份是甲哨唑耐药菌珠。对包含全长RdxA基因的Hp临床菌珠的核心蛋白簇进行序列比对分析。对耐药菌珠与敏感菌珠的差异位点进行分析,以鉴定出差异基因及其导致甲硝唑耐药的氨基酸改变。结果:在73份甲硝唑耐药菌珠中,25份(34%)是由于RdxA无义突变所导致。对来自剩余48份甲硝唑耐药菌珠和48份甲硝唑敏感菌株的核心蛋白簇进行分析发现,有4个差异位点与甲硝唑耐药显著相关。这4个位点包括RdxA的R16H/C位点、内膜蛋白RclC(HP0565)的D85N位点、biotin carboxylase蛋白(HP0370)的V265I位点和putative threonylcarbamoyl-AMP合酶(HP0918)的A51V/T位点。结论:我们发现了Hp对甲硝唑耐药的一些新的潜在机制,值得进一步研究。 | Eng-Guan Chua Aleksandra W.Debowski KMary Webberley Fanny Peters Binit Lamichhane Mun-Fai Loke Jamuna Vadivelu Chin-Yen Tay Barry J.Marshall Michael J.Wise | 2019 | Gastroenterology Report2019，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员